These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12812390)

  • 1. Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients.
    Borawski J; Naumnik B; Myśliwiec M
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):173-4. PubMed ID: 12812390
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin and cardiovascular risk.
    Allegra V; Martimbianco L; Mengozzi G; Vasile A
    Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.
    Borawski J; Myśliwiec M
    Clin Appl Thromb Hemost; 2002 Jan; 8(1):77-84. PubMed ID: 11991244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 6. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 7. Subcutaneous erythropoietin in the treatment of renal anaemia.
    Drinovec J; Varl J
    Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemoglobin concentrations in chronic kidney disease.
    Steinbrook R
    Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of erythropoietin on cardiovascular diseases.
    Sunder-Plassmann G; Hörl WH
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S20-5. PubMed ID: 11576916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 14. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 16. [Advances in therapy of renal anemia: darbepoetin alfa].
    Schaefer R
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 20. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A; Green PJ; Lee HA
    Clin Lab Haematol; 1991; 13(3):251-3. PubMed ID: 1794227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.